Drug Design Development and Therapy · 2018 · 54 citations · 24 references
MedicineOncologyPharmacologyApoptosisCell SignalingMolecular OncologyApoptosis PharmacologyApoptosis ResistanceCancer ChemopreventionColorectal CancerAnticancer ActivityAnticancer Natural ProductsCell Viability AssaysGlycogen Synthase Kinase 3 RegulationGlycogen Synthase Kinase 3 SignalingMedicinal Plant ResourcesWnt In CancerWnt Signaling In Proliferation
Background: Colorectal cancer (CRC) is among highest prevailing cancers in the whole world, especially in western countries. For a diverse of reasons, patients prefer naturally occurring dietary substances over synthetic agents to prevent cancer. Vicenin-2 is largely available in a medicinal plant Ocimum sanctum and is an apigenin form, 6,8-di-C-glucoside, which has been reported to have a range of pharmacological values which includes antioxidant, hepatoprotective, anti-inflammatory and anti-cancer. This study was aimed to analyze the anti-proliferative effect of Vicenin-2 on human colon cancer cells via the Wnt/β-catenin signaling inhibition. Methods: MTT assay was used to assess the cell viability at different concentrations and time point. Vicenin-2 at a concentration of 50 μM (IC 50 ) decreased the phosphorylated (inactive) glycogen synthase kinase-3β, cyclin D1, and non-p-β-catenin expressions in HT-29 cells, which were evidenced through western blot analysis. Results: Further, Vincenin-2 reduced the T-cell factor (TCF) / Leukocyte erythroid factor (LEF) reporter activity in HT-29 cells. Vicenin-2 also promoted substantial cell cycle arrest at the G 2 M phase of HT-29 cells, as well induced apoptosis in HT-29 cells, as revealed through flow cytometric analysis. Furthermore, immunoblot analysis showed that Vicenin-2 treatment enhanced the expression of Cytochrome C, Bax and caspase-3 whereas suppressed the Bcl-2 expression. Conclusion: Together, these results revealed that Vicenin-2 can act as a potent inhibitor of HT-29 cell proliferation and can be used as an agent against CRC. Keywords: colorectal cancer, Vicenin-2, β-catenin, apoptosis, caspase-3
24
Rebecca L. Siegel, Kimberly D. Miller, Ahmedin Jemal · CA A Cancer Journal for Clinicians · 2016 · 16.2K citations · Full text
Colorectal cancer statistics, 2023
Rebecca L. Siegel, Nikita Sandeep Wagle, Andrea Cercek et al. · CA A Cancer Journal for Clinicians · 2023 · 3.8K citations · Full text
Colorectal cancer statistics, 2014
Rebecca L. Siegel, Carol DeSantis, Ahmedin Jemal · CA A Cancer Journal for Clinicians · 2014 · 2.6K citations · Full text